Presentations and Publications
11/10/2022
XTX202 Poster Presentation at the 2022 Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
XTX202, a tumor-selective protein-engineered IL-2, exhibited enhanced anti-tumor activity in combination with checkpoint inhibition in mice
06/05/2022
XTX202 Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202, a Tumor-Selective Interleukin-2 (IL-2), in Patients with Advanced Solid Tumors
05/10/2022
XTX301 Poster Presentation at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2022 Conference
A half-life extended, tumor selective IL-12 activated tumor infiltrating immune cells and demonstrated anti-tumor activity in the MC38 syngeneic mouse model
11/12/2021
XTX301 Poster Presentation at the Society for Immunotherapy in Cancer’s 36th Annual Meeting (SITC)
XTX301, A Protein-engineered IL-12, Exhibits Tumor-selective Activity In Mice Without Peripheral Toxicities And Is Well Tolerated In Non-Human Primates
More XILIO News
11/12/2021
XTX101 (CTLA-4) Poster Presentation at the Society for Immunotherapy in Cancer’s 36th Annual Meeting (SITC)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors
10/17/2021
Poster Presentation at the 9th Annual Meeting of the International Cytokine and Interferon Society (ICIS)
Engineering Geographically Precise Activation of Cytokines To Achieve Improved Therapeutic Benefit in Oncology and Beyond
09/22/2021
Presentation at the Next-Gen Cytokine Therapeutics Summit
Tumor selective cytokines for cancer therapy
06/08/2021
XTX202 (IL-2) Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
XTX202, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates
05/12/2021
XTX101 (CTLA-4) Poster Presentation at The New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021 Virtual Symposium
Tumor-Activated Anti-CTLA-4 Monoclonal Antibody, XTX101, Demonstrates Monotherapy and Anti-PD-1 Combination Benefit in Preclinical Models
11/13/2020
XTX101 (CTLA-4) Poster Presentation at 35th Annual Meeting of The Society for Immunotherapy of Cancer
Tumor-activated Fc-engineered Anti-CTLA-4 Monoclonal Antibody, XTX101, Demonstrates Tumor-selective PD and Efficacy in Preclinical Models
11/12/2020
XTX201 (IL-2) Poster Presentation at 35th Annual Meeting of The Society for Immunotherapy of Cancer
XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates